Beyond Glycemic Control: Periodontal, Salivary, and Oral Microbiome Effects of GLP-1 Receptor Agonists—A Scoping Review of Clinical and Preclinical Evidence

Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to treat type 2 diabetes and obesity, yet their periodontal, peri-implant, salivary, and oral microbial effects remain incompletely characterized. This scoping review mapped the clinical and preclinical evidence on GLP-1RA-related oral effects, investigated mechanisms, and knowledge gaps. Methods: PubMed, Scopus, and the Web of Science Core Collection were searched from inception to 9 September 2026. Original human, animal in vivo, in vitro/ex vivo, and mixed-design studies were eligible when a GLP-1RA was a principal intervention or exposure and a relevant oral or orofacial outcome was reported. Two reviewers independently screened records. Study characteristics, interventions, outcomes, and findings were charted and synthesized descriptively. The review followed Joanna Briggs Institute methodology and PRISMA-ScR guidance and was registered on the Open Science Framework after study selection but before completion of the methodological appraisal and manuscript. Results: Twenty-seven publications were included, 23 of which were wholly or partly preclinical. Four publications were exclusively human, and one mixed-design publication included an additional human observational component. Experimental findings suggested anti-inflammatory, antioxidant, and osteogenic effects, but molecular responses were not consistently accompanied by structural benefits. Evidence concerning salivary function, oral microbial changes, and orofacial adverse events was limited and heterogeneous. Human findings were derived from non-randomized observational and descriptive designs. Conclusions: Evidence of potential oral effects is predominantly experimental, and human data are insufficient to establish clinical benefit or causality. Prospective controlled studies with standardized clinical outcomes are needed to determine whether experimental findings translate into meaningful oral-health benefits.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-11-02
DOI
https://doi.org/10.3390/pharmaceutics18111410
Primary Topic
Oral microbiology and periodontitis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond Glycemic Control: Periodontal, Salivary, and Oral Microbiome Effects of GLP-1 Receptor Agonists—A Scoping Review of Clinical and Preclinical Evidence

Atena Găluşcan, Octavia Bălean, Daniela Elisabeta Jumanca, Doina Chioran et al.
2 links
Pharmaceutics
Oral microbiology and periodontitis research
article

Beyond Glycemic Control: Periodontal, Salivary, and Oral Microbiome Effects of GLP-1 Receptor Agonists—A Scoping Review of Clinical and Preclinical Evidence

Atena Găluşcan, Octavia Bălean, Daniela Elisabeta Jumanca, Doina Chioran, Ramona Dumitrescu, Simona Daniela Popescu, Vlad Tiberiu Alexa, Aurora Doris Fratila, Vanessa Bolchis, Lucian Floare, Delia Abrudan-Luca, Oana Pirvu
article en

Abstract

Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to treat type 2 diabetes and obesity, yet their periodontal, peri-implant, salivary, and oral microbial effects remain incompletely characterized. This scoping review mapped the clinical and preclinical evidence on GLP-1RA-related oral effects, investigated mechanisms, and knowledge gaps. Methods: PubMed, Scopus, and the Web of Science Core Collection were searched from inception to 9 September 2026. Original human, animal in vivo, in vitro/ex vivo, and mixed-design studies were eligible when a GLP-1RA was a principal intervention or exposure and a relevant oral or orofacial outcome was reported. Two reviewers independently screened records. Study characteristics, interventions, outcomes, and findings were charted and synthesized descriptively. The review followed Joanna Briggs Institute methodology and PRISMA-ScR guidance and was registered on the Open Science Framework after study selection but before completion of the methodological appraisal and manuscript. Results: Twenty-seven publications were included, 23 of which were wholly or partly preclinical. Four publications were exclusively human, and one mixed-design publication included an additional human observational component. Experimental findings suggested anti-inflammatory, antioxidant, and osteogenic effects, but molecular responses were not consistently accompanied by structural benefits. Evidence concerning salivary function, oral microbial changes, and orofacial adverse events was limited and heterogeneous. Human findings were derived from non-randomized observational and descriptive designs. Conclusions: Evidence of potential oral effects is predominantly experimental, and human data are insufficient to establish clinical benefit or causality. Prospective controlled studies with standardized clinical outcomes are needed to determine whether experimental findings translate into meaningful oral-health benefits.

PharmaceuticsVol. 18(11)
Spitalul Clinic Judeţean de Urgenţă "Pius Brînzeu" Timişoara (RO), Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
Good health and well-being
Openalex Percentile: Top 11%
Oral microbiology and periodontitis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon